|
1
|
Giordano SH, Temin S, Kirshner JJ,
Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo
AM, Krop I, Levinson J, et al: American Society of Clinical
Oncology: Systemic therapy for patients with advanced human
epidermal growth factor receptor 2-positive breast cancer: American
Society of Clinical Oncology clinical practice guideline. J Clin
Oncol. 32:2078–2099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM,
Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et
al: HER2 screening data from ToGA: Targeting HER2 in gastric and
gastro-esophageal junction cancer. Gastric Cancer. 18:476–484.
2015. View Article : Google Scholar
|
|
3
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar
|
|
5
|
de Azambuja E, Holmes AP, Piccart-Gebhart
M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I,
Smith I, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): Survival outcomes of a randomised,
open-label, multicentre, phase 3 trial and their association with
pathological complete response. Lancet Oncol. 15:1137–1146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al American Society of Clinical Oncology: College
of American Pathologists: Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American Society
of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Foukakis T, Åström G, Lindström L,
Hatschek T and Bergh J: When to order a biopsy to characterise a
metastatic relapse in breast cancer. Ann Oncol. 23(Suppl 10):
x349–x353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Houssami N, Macaskill P, Balleine RL,
Bilous M and Pegram MD: HER2 discordance between primary breast
cancer and its paired metastasis: Tumor biology or test artefact?
Insights through meta-analysis. Breast Cancer Res Treat.
129:659–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilking U, Karlsson E, Skoog L, Hatschek
T, Lidbrink E, Elmberger G, Johansson H, Lindström L and Bergh J:
HER2 status in a population-derived breast cancer cohort:
Discordances during tumor progression. Breast Cancer Res Treat.
125:553–561. 2011. View Article : Google Scholar
|
|
11
|
Krasniqi A, D’Huyvetter M, Devoogdt N,
Frejd FY, Sörensen J, Orlova A, Keyaerts M and Tolmachev V:
Same-day imaging using small proteins: Clinical experience and
translational prospects in oncology. J Nucl Med. 59:885–891. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Orlova A, Magnusson M, Eriksson TL,
Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J,
Tolmachev V, Ståhl S, et al: Tumor imaging using a picomolar
affinity HER2 binding affibody molecule. Cancer Res. 66:4339–4348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garousi J, Lindbo S, Nilvebrant J, Åstrand
M, Buijs J, Sandström M, Honarvar H, Orlova A, Tolmachev V and
Hober S: ADAPT, a novel scaffold protein-based probe for
radionuclide imaging of molecular targets that are expressed in
disseminated cancers. Cancer Res. 75:4364–4371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hackel BJ, Kimura RH and Gambhir SS: Use
of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor
xenograft: Molecular imaging. Radiology. 263:179–188. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang L, Tu Y, Kimura RH, Habte F, Chen H,
Cheng K, Shi H, Gambhir SS and Cheng Z: 64Cu-labeled divalent
cystine knot peptide for imaging carotid atherosclerotic Plaques. J
Nucl Med. 56:939–944. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Terwisscha van Scheltinga AG, Lub-de Hooge
MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast
WB, Schröder CP, Kosterink JG, de Vries EG, et al: In vivo
visualization of MET tumor expression and anticalin biodistribution
with the MET-specific anticalin 89Zr-PRS-110 P ET tracer. J Nucl
Med. 55:665–671. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sörensen J, Velikyan I, Sandberg D,
Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M,
Lubberink M, Olofsson H, et al: Measuring HER2-receptor expression
in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/ CT.
Theranostics. 6:262–271. 2016. View Article : Google Scholar
|
|
18
|
Binz HK, Stumpp MT, Forrer P, Amstutz P
and Plückthun A: Designing repeat proteins: Well-expressed, soluble
and stable proteins from combinatorial libraries of consensus
ankyrin repeat proteins. J Mol Biol. 332:489–503. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
The European Union Clinical Trials
Register [Internet]: EudraCT Number 2011-002526-43. Single and
Repeat Dose Study of the Safety and Efficacy of AGN-150998 in
Patients with Exudative Age-related Macular Degeneration.
https://www.clinicaltrial-sregister.eu/ctr-search/search?query=2011-002526-43
Accessed January 30, 2012.
|
|
20
|
Zahnd C, Kawe M, Stumpp MT, de Pasquale C,
Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK,
Waibel R, et al: Efficient tumor targeting with high-affinity
designed ankyrin repeat proteins: Effects of affinity and molecular
size. Cancer Res. 70:1595–1605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raguin O, Leblanc L, Collin B, Oudot A,
Mirjolet JF, Fiedler U and Dolado I: Biodistribution and antitumor
efficacy study of novel Her2 targeting DARPins. Cancer Res.
74(Suppl 19): Abstract 5442. 2014. View Article : Google Scholar
|
|
22
|
Fiedler U, Metz C, Zitt C, Bessey R, Béhé
M, Blanc A, Schibli R, Dolado I, Herbst J, Dawson KM and
Kiemle-Kallee J: Pre-clinical antitumor activity, tumor
localization, and pharmacokinetics of MP0274, an apoptosis
inducing, biparatopic HER2-targeting DARPin. Cancer Res. 77(Suppl
4): Abstract P4-21-18. 2017. View Article : Google Scholar
|
|
23
|
ClinicalTrials.gov [Internet]. Bethesda
(MD): National Library of Medicine (US). Identifier NCT03084926.
First-in-human Study to Investigate Safety, Blood Levels and
Activity of MP0274 in Cancer Patients With HER2-positive Solid
Tumors. Accessed December 18, 2018. https://clinicaltrials.gov/ct2/show/NCT03084926.
|
|
24
|
Goldstein R, Sosabowski J, Livanos M,
Leyton J, Vigor K, Bhavsar G, Nagy-Davidescu G, Rashid M, Miranda
E, Yeung J, et al: Development of the designed ankyrin repeat
protein (DARPin) G3 for HER2 molecular imaging. Eur J Nucl Med Mol
Imaging. 42:288–301. 2015. View Article : Google Scholar :
|
|
25
|
Vorobyeva A, Bragina O, Altai M, Mitran B,
Orlova A, Shulga A, Proshkina G, Chernov V, Tolmachev V and Deyev
S: Comparative evaluation of radioiodine and technetium-labeled
DARPin 9_29 for radionuclide molecular imaging of HER2 expression
in malignant tumors. Contrast Media Mol Imaging.
2018.6930425:2018.
|
|
26
|
Steffen AC, Wikman M, Tolmachev V, Adams
GP, Nilsson FY, Ståhl S and Carlsson J: In vitro characterization
of a bivalent anti-HER-2 affibody with potential for
radionuclide-based diagnostics. Cancer Biother Radiopharm.
20:239–248. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zalutsky MR and Narula AS: A method for
the radiohalogenation of proteins resulting in decreased thyroid
uptake of radioiodine. Int J Rad Appl Instrum. 38:1051–1055. 1987.
View Article : Google Scholar
|
|
28
|
Rea DW, Ultee ME, Belinka BA Jr, Coughlin
DJ and Alvarez VL: Site-specifically radioiodinated antibody for
targeting tumors. Cancer Res. 50(Suppl 3): 857s–861s.
1990.PubMed/NCBI
|
|
29
|
Malakhov MP, Mattern MR, Malakhova OA,
Drinker M, Weeks SD and Butt TR: SUMO fusions and SUMO-specific
protease for efficient expression and purification of proteins. J
Struct Funct Genomics. 5:75–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heckman KL and Pease LR: Gene splicing and
mutagenesis by PCR-driven overlap extension. Nat Protoc. 2:924–932.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Studier FW: Protein production by
auto-induction in high density shaking cultures. Protein Expr
Purif. 41:207–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tolmachev V, Tran TA, Rosik D, Sjöberg A,
Abrahmsén L and Orlova A: Tumor targeting using affibody molecules:
Interplay of affinity, target expression level, and binding site
composition. J Nucl Med. 53:953–960. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McLarty K, Cornelissen B, Scollard DA,
Done SJ, Chun K and Reilly RM: Associations between the uptake of
111In-DTPA-trastuzumab, HER2 density and response to trastuzumab
(Herceptin) in athymic mice bearing subcutaneous human tumour
xenografts. Eur J Nucl Med Mol Imaging. 36:81–93. 2009. View Article : Google Scholar
|
|
34
|
Malmberg J, Tolmachev V and Orlova A:
Imaging agents for in vivo molecular profiling of disseminated
prostate cancer: Cellular processing of [(111)In]-labeled
CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate
cancer cell lines. Exp Ther Med. 2:523–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Björkelund H, Gedda L, Barta P, Malmqvist
M and Andersson K: Gefitinib induces epidermal growth factor
receptor dimers which alters the interaction characteristics with
125I-EGF. PLoS One. 6:e247392011. View Article : Google Scholar :
|
|
36
|
Tolmachev V, Orlova A and Andersson K:
Methods for radio-labelling of monoclonal antibodies. Methods Mol
Biol. 1060:309–330. 2014. View Article : Google Scholar
|
|
37
|
Wyszomirska A: Iodine-131 for therapy of
thyroid diseases. Physical and biological basis Nucl Med Rev Cent
East Eur. 15:120–123. 2012.
|
|
38
|
Mume E, Orlova A, Larsson B, Nilsson A-S,
Nilsson FY, Sjöberg S and Tolmachev V: Evaluation of
((4-hydroxyphenyl) ethyl)maleimide for site-specific
radiobromination of anti-HER2 affibody. Bioconjug Chem.
16:1547–1555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lindbo S, Garousi J, Mitran B, Altai M,
Buijs J, Orlova A, Hober S and Tolmachev V: Radionuclide tumor
targeting using ADAPT scaffold proteins: Aspects of label
positioning and residualizing properties of the label. J Nucl Med.
59:93–99. 2018. View Article : Google Scholar
|
|
40
|
Shih LB, Thorpe SR, Griffiths GL, Diril H,
Ong GL, Hansen HJ, Goldenberg DM and Mattes MJ: The processing and
fate of antibodies and their radiolabels bound to the surface of
tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med.
35:899–908. 1994.PubMed/NCBI
|
|
41
|
Wållberg H, Orlova A, Altai M,
Hosseinimehr SJ, Widström C, Malmberg J, Ståhl S and Tolmachev V:
Molecular design and optimization of 99mTc-labeled recombinant
affibody molecules improves their biodistribution and imaging
properties. J Nucl Med. 52:461–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Altai M, Honarvar H, Wållberg H, Strand J,
Varasteh Z, Rosestedt M, Orlova A, Dunås F, Sandström M, Löfblom J,
et al: Selection of an optimal cysteine-containing peptide-based
chelator for labeling of affibody molecules with (188)Re. Eur J Med
Chem. 87:519–528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Engfeldt T, Orlova A, Tran T, Bruskin A,
Widström C, Karlström AE and Tolmachev V: Imaging of
HER2-expressing tumours using a synthetic Affibody molecule
containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl
(MAG3) sequence. Eur J Nucl Med Mol Imaging. 34:722–733. 2007.
View Article : Google Scholar
|
|
44
|
Halmi NS and Stuelke RG: Comparison of
thyroidal and gastric iodide pumps in rats. Endocrinology.
64:103–109. 1959. View Article : Google Scholar : PubMed/NCBI
|
